Peiyao Li

Peiyao Li

Auto-generated profile, based on publicly available information

Peiyao Li

Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2021 in Science Advances
Verified
Journal Article
Open access
PCPengbo Cao
Pengbo Cao
AYAiqing Yang
Aiqing Yang
PLPeiyao Li
Peiyao Li
XXXia Xia
Xia Xia
YHYuqing Han
Yuqing Han
GZGangqiao Zhou
Gangqiao Zhou
RRS1 is a chromosome 8q oncogene that couples ribosome biogenesis to RPL11-MDM2-p53 signaling in hepatocellular carcinoma.

22 November 2020 in Journal of Molecular Histology
Verified
Journal Article
Open access
PDF file
PLPeiyao Li
Peiyao Li
HJHuiru Jing
Huiru Jing
YWYanzhe Wang
Yanzhe Wang
LYLei Yuan
Lei Yuan
HXHui Xiao
Hui Xiao
QZQian Zheng
Qian Zheng
Apoptosis and clearance of dead cells is highly evolutionarily conserved from nematode to humans, which is crucial to the growth and development of multicellular organism. Fail to remove apoptotic cells often lead to homeostasis imbalance, fatal autoimmune diseases, and neurodegenerative diseases. Small ubiquitin-related modifiers (SUMOs) modification is a post-translational modification of ubiquitin proteins mediated by the sentrin-specific proteases (SENPs) family. SUMO modification is widely involved in many cellular biological process, and abnormal SUMO modification is also closely related to many major human diseases. Recent researches have revealed that SUMO modification event occurs during apoptosis and clearance of apoptotic cells, and plays an important role in the regulation of apoptotic signaling pathways. This review summarizes some recent progress in the revelation of regulatory mechanisms of these pathways and provides some potential researching hotpots of the SUMO modification regulation to apoptosis.

7 September 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SSSandra Santasusagna
Sandra Santasusagna
SZShijia Zhu
Shijia Zhu
VJVijayakumar Jawalagatti
Vijayakumar Jawalagatti
MCMarc Carceles-Cordon
Marc Carceles-Cordon
AEAdam Ertel
Adam Ertel
JDJosep Domingo-Domenech
Josep Domingo-Domenech
Signaling rewiring allows tumors to survive therapy. Here we show that the decrease of the master regulator microphthalmia transcription factor (MITF) in lethal prostate cancer unleashes eukaryotic initiation factor 3B (eIF3B)–dependent translation reprogramming of key mRNAs conferring resistance to androgen deprivation therapy (ADT) and promoting immune evasion. Mechanistically, MITF represses through direct promoter binding eIF3B, which in turn regulates the translation of specific mRNAs. Genome-wide eIF3B enhanced cross-linking immunoprecipitation sequencing (eCLIP-seq) showed specialized binding to a UC-rich motif present in subsets of 5′ untranslated regions. Indeed, translation of the androgen receptor and major histocompatibility complex I (MHC-I) through this motif is sensitive to eIF3B amount. Notably, pharmacologic targeting of eIF3B-dependent translation in preclinical models sensitizes prostate cancer to ADT and anti–PD-1 therapy. These findings uncover a hidden connection between transcriptional and translational rewiring promoting therapy-refractory lethal prostate cancer and provide a druggable mechanism that may transcend into effective combined therapeutic strategies. Significance: Our study shows that specialized eIF3B-dependent translation of specific mRNAs released upon downregulation of the master transcription factor MITF confers castration resistance and immune evasion in lethal prostate cancer. Pharmacologic targeting of this mechanism delays castration resistance and increases immune-checkpoint efficacy. This article is featured in Selected Articles from This Issue, p. 2489

1 December 2023 in Science Immunology
Verified
Journal Article
Closed access
YSYi Sun
Yi Sun
TFTyler J. Florio
Tyler J. Florio
SGSagar Gupta
Sagar Gupta
MYMichael C. Young
Michael C. Young
QMQuinlen F. Marshall
Quinlen F. Marshall
NSNikolaos G. Sgourakis
Nikolaos G. Sgourakis
Peptide-centric chimeric antigen receptors (PC-CARs) recognize oncoprotein epitopes displayed by cell-surface human leukocyte antigens (HLAs) and offer a promising strategy for targeted cancer therapy. We have previously developed a PC-CAR targeting a neuroblastoma-associated PHOX2B peptide, leading to robust tumor cell lysis restricted by two common HLA allotypes. Here, we determine the 2.1-angstrom crystal structure of the PC-CAR–PHOX2B–HLA-A*24:02–β 2 m complex, which reveals the basis for antigen-specific recognition through interactions with CAR complementarity-determining regions (CDRs). This PC-CAR adopts a diagonal docking mode, where interactions with both conserved and polymorphic HLA framework residues permit recognition of multiple HLA allotypes from the A9 serological cross-reactive group, covering a combined global population frequency of up to 46.7%. Biochemical binding assays, molecular dynamics simulations, and structural and functional analyses demonstrate that high-affinity PC-CAR recognition of cross-reactive pHLAs necessitates the presentation of a specific peptide backbone, where subtle structural adaptations of the peptide are critical for high-affinity complex formation, and CAR T cell killing. Our results provide a molecular blueprint for engineering CARs with optimal recognition of tumor-associated antigens in the context of different HLAs, while minimizing cross-reactivity with self-epitopes.

28 July 2025 in Cancer Discovery
Verified
Journal Article
Open access
Perumalraja kirthikaPerumalraja kirthika
Perumalraja kirthika
VJVijayakumar Jawalagatti
Vijayakumar Jawalagatti
PLPeiyao Li
Peiyao Li
Michael XuMichael Xu
Michael Xu
MCMarc Carceles-Cordon
Marc Carceles-Cordon
VRVeronica Rodriguez-Bravo
Veronica Rodriguez-Bravo
The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors. Significance: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.

2 January 2026 in Science Advances
Verified
Journal Article
Open access
DHDaniel Hwang
Daniel Hwang
MEMolly C. Erdman
Molly C. Erdman
SASantosh Adhikari
Santosh Adhikari
RPRam Pantula
Ram Pantula
KEKaya Epstein
Kaya Epstein
NSNikolaos G. Sgourakis
Nikolaos G. Sgourakis
Epitopic peptides presented by class-I human leukocyte antigen (HLA-I) proteins provide the basis of immune surveillance by T cells. Conversely, reduced surface HLA-I expression is a hallmark of immune evasion by latent viral infections and cancer, which confounds the identification of peptide antigens and neoantigens. Here, we outline a system (HLA-Shuttle) for in vitro manipulation of cells with engineered components of the HLA-I processing machinery to confer a continuum of chaperoning activity throughout their trafficking pathway. HLA-Shuttle restores antigen presentation in immunologically cold neuroblastoma cells, enabling identification of multiple tumor-associated antigens with therapeutic potential. Cellular trafficking assays and single-particle tracking reveal a global stabilization of HLA-I molecules, extension of their cell-surface lifetime and microdomain formation. HLA-Shuttle can be used across a range of aberrant cellular states where low antigen expression remains a bottleneck for the identification of endogenous peptide antigens.